|
[1]
|
Allegra, A., Innao, V., Allegra, A.G., et al. (2020) Antitumorigenic Action of Nelfinavir: Effects on Multiple Myeloma and Hematologic Malignancies (Review). Oncology Reports, 43, 1729-1736.
[Google Scholar] [CrossRef] [PubMed]
|
|
[2]
|
Marino, G., Niso-Santano, M., Baehrecke, E.H., et al. (2014) Self-Consumption: The Interplay of Autophagy and Apoptosis. Nature Reviews Molecular Cell Biology, 15, 81-94.
[Google Scholar] [CrossRef] [PubMed]
|
|
[3]
|
Nazio, F., Strappazzon, F., Antonioli, M., et al. (2013) mTOR Inhibits Autophagy by Controlling ULK1 Ubiquitylation, Self-Association and Function through AMBRA1 and TRAF6. Nature Cell Biology, 15, 406-416.
[Google Scholar] [CrossRef] [PubMed]
|
|
[4]
|
Dikic, I. and Elazar, Z. (2018) Mechanism and Medical Implications of Mammalian Autophagy. Nature Reviews Molecular Cell Biology, 19, 349-364.
[Google Scholar] [CrossRef] [PubMed]
|
|
[5]
|
Gozuacik, D. and Kimchi, A. (2004) Autophagy as a Cell Death and Tumor Suppressor Mechanism. Oncogene, 23, 2891-2906.
[Google Scholar] [CrossRef] [PubMed]
|
|
[6]
|
Vanzo, R., Bartkova, J., Merchut-Maya, J.M., et al. (2020) Autophagy Role(s) in Response to Oncogenes and DNA Replication Stress. Cell Death & Differentiation, 27, 1134-1153.
[Google Scholar] [CrossRef] [PubMed]
|
|
[7]
|
Aronson, L.I. and Davies, F.E. (2012) DangER: Protein ovERload. Targeting Protein Degradation to Treat Myeloma. Haematologica, 97, 1119-1130.
[Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
Davenport, E.L., Moore, H.E., Dunlop, A.S., et al. (2007) Heat Shock Protein Inhibition Is Associated with Activation of the Unfolded Protein Response Pathway in Myeloma Plasma Cells. Blood, 110, 2641-2649.
[Google Scholar] [CrossRef] [PubMed]
|
|
[9]
|
Di Lernia, G., Leone, P., Solimando, A.G., et al. (2020) Bortezomib Treatment Modulates Autophagy in Multiple Myeloma. Journal of Clinical Medicine, 9, 552.
[Google Scholar] [CrossRef] [PubMed]
|
|
[10]
|
Hideshima, T., Mitsiades, C., Akiyama, M., et al. (2003) Molecular Mechanisms Mediating Antimyeloma Activity of Proteasome Inhibitor PS-341. Blood, 101, 1530-1534.
[Google Scholar] [CrossRef] [PubMed]
|
|
[11]
|
Leblanc, R., Catley, L.P., Hideshima, T., et al. (2002) Proteasome Inhibitor PS-341 Inhibits Human Myeloma Cell Growth in Vivo and Prolongs Survival in a Murine Model. Cancer Research, 62, 4996-5000.
|
|
[12]
|
Hamouda, M.A., Belhacene, N., Puissant, A., et al. (2014) The Small Heat Shock Protein B8 (HSPB8) Confers Resistance to Bortezomib by Promoting Autophagic Removal of Misfolded Proteins in Multiple Myeloma Cells. Oncotarget, 5, 6252-6266.
[Google Scholar] [CrossRef] [PubMed]
|
|
[13]
|
Jaganathan, S., Malek, E., Vallabhapurapu, S., et al. (2014) Bortezomib Induces AMPK-Dependent Autophagosome Formation Uncoupled from Apoptosis in Drug Resistant Cells. Oncotarget, 5, 12358-12370.
[Google Scholar] [CrossRef] [PubMed]
|
|
[14]
|
Vogl, D.T., Stadtmauer, E.A., Tan, K.S., et al. (2014) Combined Autophagy and Proteasome Inhibition: A Phase 1 Trial of Hydroxychloroquine and Bortezomib in Patients with Relapsed/Refractory Myeloma. Autophagy, 10, 1380-1390.
[Google Scholar] [CrossRef] [PubMed]
|
|
[15]
|
Zhang, L., Rastgoo, N., Wu, J., et al. (2020) MARCKS Inhibition Cooperates with Autophagy Antagonists to Potentiate the Effect of Standard Therapy against Drug-Resistant Multiple Myeloma. Cancer Letters, 480, 29-38.
[Google Scholar] [CrossRef] [PubMed]
|
|
[16]
|
Parker, J.E., Mufti, G.J., Rasool, F., et al. (2000) The Role of Apoptosis, Proliferation, and the Bcl-2-Related Proteins in the Myelodysplastic Syndromes and Acute Myeloid Leukemia Secondary to MDS. Blood, 96, 3932-3938.
[Google Scholar] [CrossRef]
|
|
[17]
|
Messa, E., Cilloni, D., Messa, F., et al. (2008) Deferasirox Treatment Improved the Hemoglobin Level and Decreased Transfusion Requirements in Four Patients with the Myelodysplastic Syndrome and Primary Myelofibrosis. Acta Haematologica, 120, 70-74.
[Google Scholar] [CrossRef] [PubMed]
|
|
[18]
|
Banerjee, A., Mifsud, N.A., Bird, R., et al. (2015) The Oral Iron Chelator Deferasirox Inhibits NF-kappaB Mediated Gene Expression without Impacting on Proximal Activation: Implications for Myelodysplasia and Aplastic Anaemia. British Journal of Haematology, 168, 576-582.
[Google Scholar] [CrossRef] [PubMed]
|
|
[19]
|
Jiang, H., Yang, L., Guo, L., et al. (2018) Impaired Mitophagy of Nucleated Erythroid Cells Leads to Anemia in Patients with Myelodysplastic Syndromes. Oxidative Medicine and Cellular Longevity, 2018, Article ID: 6328051.
[Google Scholar] [CrossRef] [PubMed]
|
|
[20]
|
Houwerzijl, E.J., Pol, H.W., Blom, N.R., et al. (2009) Erythroid Precursors from Patients with Low-Risk Myelodysplasia Demonstrate Ultrastructural Features of Enhanced Autophagy of Mitochondria. Leukemia, 23, 886-891.
[Google Scholar] [CrossRef] [PubMed]
|
|
[21]
|
Park, S.M., Ou, J., Chamberlain, L., et al. (2016) U2AF35(S34F) Promotes Transformation by Directing Aberrant ATG7 Pre-mRNA 3’ End Formation. Molecular Cell, 62, 479-490.
[Google Scholar] [CrossRef] [PubMed]
|
|
[22]
|
Raj, K., John, A., Ho, A., et al. (2007) CDKN2B Methylation Status and Isolated Chromosome 7 Abnormalities Predict Responses to Treatment with 5-Azacytidine. Leukemia, 21, 1937-1944.
[Google Scholar] [CrossRef] [PubMed]
|
|
[23]
|
Romano, A., Giallongo, C., La Cava, P., et al. (2017) Proteomic Analysis Reveals Autophagy as Pro-Survival Pathway Elicited by Long-Term Exposure with 5-Azacitidine in High-Risk Myelodysplasia. Frontiers in Pharmacology, 8, 204.
[Google Scholar] [CrossRef] [PubMed]
|
|
[24]
|
Robert, G. and Auberger, P. (2019) Azacitidine Resistance Caused by LAMP2 Deficiency: A Therapeutic Window for the Use of Autophagy Inhibitors in MDS/AML Patients? Autophagy, 15, 927-929.
[Google Scholar] [CrossRef] [PubMed]
|
|
[25]
|
刘艳芬, 刘欣, 訾建杰, 等. HAG联合地西他滨对骨髓增生异常综合征患者凋亡自噬相关基因表达的影响[J]. 河北医药, 2021, 43(6): 890-893.
|
|
[26]
|
Flis, S. and Chojnacki, T. (2019) Chronic Myelogenous Leukemia, a Still Unsolved Problem: Pitfalls and New Therapeutic Possibilities. Drug Design, Development and Therapy, 13, 825-843.
[Google Scholar] [CrossRef]
|
|
[27]
|
Kollmann, S., Grundschober, E., Maurer, B., et al. (2019) Twins with Different Personalities: STAT5B—But Not STAT5A—Has a Key Role in BCR/ABL-Induced Leukemia. Leukemia, 33, 1583-1597.
[Google Scholar] [CrossRef] [PubMed]
|
|
[28]
|
Dinner, S. and Platanias, L.C. (2016) Targeting the mTOR Pathway in Leukemia. Journal of Cellular Biochemistry, 117, 1745-1752.
[Google Scholar] [CrossRef] [PubMed]
|
|
[29]
|
de Cassia, V.C.R., Fontes, A.M., Abraham, K.J., et al. (2018) Expression Differences of Genes in the PI3K/AKT, WNT/b-Catenin, SHH, NOTCH and MAPK Signaling Pathways in CD34+ Hematopoietic Cells Obtained from Chronic Phase Patients with Chronic Myeloid Leukemia and from Healthy Controls. Clinical and Translational Oncology, 20, 542-549.
[Google Scholar] [CrossRef] [PubMed]
|
|
[30]
|
韩晨阳, 杨毅, 郭丽, 等. 自噬基因Beclin1抑制后增强人髓性白血病耐药细胞K562/IMA对于伊马替尼的药物敏感性[J]. 中国药学杂志, 2019, 54(4): 284-290.
|
|
[31]
|
White, E. and Dipaola, R.S. (2009) The Double-Edged Sword of Autophagy Modulation in Cancer. Clinical Cancer Research, 15, 5308-5316.
[Google Scholar] [CrossRef]
|
|
[32]
|
Liu, Z., Zheng, W., Liu, Y., et al. (2021) Targeting HSPA8 Inhibits Proliferation via Downregulating BCR-ABL and Enhances Chemosensitivity in Imatinib-Resistant Chronic Myeloid Leukemia Cells. Experimental Cell Research, 405, Article ID: 112708.
[Google Scholar] [CrossRef] [PubMed]
|